Georgios Theocharidis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Georgios Theocharidis has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
- Aristidis Veves
Joslin-Beth Israel Deaconess Foot Center and The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
14 shared publications Aristidis Veves
Joslin-Beth Israel Deaconess Foot Center and The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
7 shared publicationsZhuqing Li
Joslin-Beth Israel Deaconess Foot Center and The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
7 shared publicationsIkram Mezghani
Joslin-Beth Israel Deaconess Foot Center and The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
6 shared publications- David J. Mooney
John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, USA
4 shared publications Enya Wang
Joslin-Beth Israel Deaconess Foot Center and The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
4 shared publications
Latest Publications
- Open Access
Cholinergic modulation engages a CHRM1-IL-17 neuroimmune axis to promote diabetic wound repair
Chronic non-healing wounds are a major complication of diabetes, where persistent inflammation fails to transition into effective tissue repair ( 1–3 ). Here we identify cholinergic modulation as a mechanism that promotes productive inflammation and diabetic wound healing. Using a healing-associated fibroblast signature derived from single-cell profiling of human diabetic foot ulcers ( 3 ), we identified the acetylcholinesterase (AChE) inhibitor metrifonate as a candidate inducer of reparative wound programs. Topical delivery accelerated healing in diabetic mice and increased acetylcholine availability within the wound. Complementary receptor pharmacology identified muscarinic acetylcholine receptor 1 (CHRM1) as the principal receptor mediating the reparative response. Transcriptomic and cellular analyses revealed early induction of IL-17-associated inflammatory programs and enrichment of CHRM1⁺NK1.1⁺ innate lymphocytes. Depletion of NK1.1⁺ cells or neutralization of IL-17A abolished the pro-healing effect, whereas spatial transcriptomics revealed treatment-associated organization of NK cells within vascular niches. Localized treatment further promoted repair in diabetic porcine wounds and human skin models. Together, these findings identify a CHRM1-IL-17 neuroimmune axis linking cholinergic modulation to diabetic wound repair and establish local AChE inhibition as a potential therapeutic strategy for chronic wounds.
Open AccessCholinergic modulation engages a CHRM1-IL-17 neuroimmune axis to promote diabetic wound repair
Chronic non-healing wounds are a major complication of diabetes, where persistent inflammation fails to transition into effective tissue repair ( 1–3 ). Here we identify cholinergic modulation as a mechanism that promotes productive inflammation and diabetic wound healing. Using a healing-associated fibroblast signature derived from single-cell profiling of human diabetic foot ulcers ( 3 ), we identified the acetylcholinesterase (AChE) inhibitor metrifonate as a candidate inducer of reparative wound programs. Topical delivery accelerated healing in diabetic mice and increased acetylcholine availability within the wound. Complementary receptor pharmacology identified muscarinic acetylcholine receptor 1 (CHRM1) as the principal receptor mediating the reparative response. Transcriptomic and cellular analyses revealed early induction of IL-17-associated inflammatory programs and enrichment of CHRM1⁺NK1.1⁺ innate lymphocytes. Depletion of NK1.1⁺ cells or neutralization of IL-17A abolished the pro-healing effect, whereas spatial transcriptomics revealed treatment-associated organization of NK cells within vascular niches. Localized treatment further promoted repair in diabetic porcine wounds and human skin models. Together, these findings identify a CHRM1-IL-17 neuroimmune axis linking cholinergic modulation to diabetic wound repair and establish local AChE inhibition as a potential therapeutic strategy for chronic wounds.
- 23 July 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (67)
Immune‐Responsive Bioinks Enable Vision‐Guided in Situ Robotic Bioprinting to Accelerate Diabetic Wound Healing
Chronic diabetic wounds remain a major clinical challenge because persistent inflammation, hypoxia, and immune dysregulation prevent the transition of macrophages from pro‐inflammatory M1 states to pro‐regenerative M2 phenotypes. Here, we report an immunomodulatory colloidal bioink that integrates zein‐based oxygen‐generating microparticles and human mesenchymal stem cells within a porous, mechanically robust matrix for adaptive in situ bioprinting. Implemented with the autonomous, intelligent, visually guided in situ robotic bioprinting platform, this bioink enables patient‐specific deposition directly onto wound defects with high spatial conformity and stable tissue integration. Sustained oxygen release alleviates local hypoxic stress, enhances stem cell survival, and reshapes the wound microenvironment to favor regenerative immune responses. In diabetic wound models, the printed constructs promote angiogenesis, accelerate wound closure, and improve tissue regeneration. Spatial transcriptomic analysis further reveals macrophage heterogeneity across wound compartments and identifies a coordinated M1‐to‐M2 transition spatially and transcriptionally associated with the combined contribution of oxygen modulation and stem cell‐derived paracrine signaling. Together, this study establishes a therapeutic strategy that combines intelligent biomaterial design, controlled hypoxic conditioning, and adaptive robotic bioprinting to achieve precision immunomodulation and personalized regenerative treatment for chronic diabetic wounds with clinical translational potential and broad future applicability.
- 23 July 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (67)
Immune‐Responsive Bioinks Enable Vision‐Guided in Situ Robotic Bioprinting to Accelerate Diabetic Wound Healing
Chronic diabetic wounds remain a major clinical challenge because persistent inflammation, hypoxia, and immune dysregulation prevent the transition of macrophages from pro‐inflammatory M1 states to pro‐regenerative M2 phenotypes. Here, we report an immunomodulatory colloidal bioink that integrates zein‐based oxygen‐generating microparticles and human mesenchymal stem cells within a porous, mechanically robust matrix for adaptive in situ bioprinting. Implemented with the autonomous, intelligent, visually guided in situ robotic bioprinting platform, this bioink enables patient‐specific deposition directly onto wound defects with high spatial conformity and stable tissue integration. Sustained oxygen release alleviates local hypoxic stress, enhances stem cell survival, and reshapes the wound microenvironment to favor regenerative immune responses. In diabetic wound models, the printed constructs promote angiogenesis, accelerate wound closure, and improve tissue regeneration. Spatial transcriptomic analysis further reveals macrophage heterogeneity across wound compartments and identifies a coordinated M1‐to‐M2 transition spatially and transcriptionally associated with the combined contribution of oxygen modulation and stem cell‐derived paracrine signaling. Together, this study establishes a therapeutic strategy that combines intelligent biomaterial design, controlled hypoxic conditioning, and adaptive robotic bioprinting to achieve precision immunomodulation and personalized regenerative treatment for chronic diabetic wounds with clinical translational potential and broad future applicability.
- Open Access
- 2 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Integrated machine learning analysis of proteomic and transcriptomic data identifies healing associated targets in diabetic wound repair
This study identified biomarkers that could be leveraged to classify the state of healing in diabetic wounds. Firstly, by collecting wound samples from diabetic mice at different time points and generating their protein profiles using standard techniques, we set to interrogate whether a small number of biomarkers could serve as sensors to monitor the healing stage. Least absolute shrinkage and selection operator (LASSO) was applied. Large-scale analysis of wound tissue proteins integrated with the respective wound sizes allowed to establish a correlation between the observed protein profile and wound closure. We further evaluated human subjects’ systemic serum proteomics for biomarkers. An additional wound healing model in diabetic mice was employed for microRNA quantitation at the same time points and similarly analyzed. Our analysis highlighted markers MMP-2, HGF, miR-1b and miR-107-3p in mice and Fractalkine and FGF-2 in humans that could correctly identify the extent of healing. By using proteomics from mice and human patients and complementary microRNA mouse data with computer regression models we can better predict molecular and protein deficits associated with impaired diabetic wound repair.
- 2 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Open AccessIntegrated machine learning analysis of proteomic and transcriptomic data identifies healing associated targets in diabetic wound repair
This study identified biomarkers that could be leveraged to classify the state of healing in diabetic wounds. Firstly, by collecting wound samples from diabetic mice at different time points and generating their protein profiles using standard techniques, we set to interrogate whether a small number of biomarkers could serve as sensors to monitor the healing stage. Least absolute shrinkage and selection operator (LASSO) was applied. Large-scale analysis of wound tissue proteins integrated with the respective wound sizes allowed to establish a correlation between the observed protein profile and wound closure. We further evaluated human subjects’ systemic serum proteomics for biomarkers. An additional wound healing model in diabetic mice was employed for microRNA quantitation at the same time points and similarly analyzed. Our analysis highlighted markers MMP-2, HGF, miR-1b and miR-107-3p in mice and Fractalkine and FGF-2 in humans that could correctly identify the extent of healing. By using proteomics from mice and human patients and complementary microRNA mouse data with computer regression models we can better predict molecular and protein deficits associated with impaired diabetic wound repair.
- Open Access
- 11 July 2025
- Published by Springer Nature in Nature
- Vol. 643 (8074) , E26
Author Correction: Adhesive anti-fibrotic interfaces on diverse organs
- 11 July 2025
- Published by Springer Nature in Nature
- Vol. 643 (8074) , E26
Open AccessAuthor Correction: Adhesive anti-fibrotic interfaces on diverse organs
- 1 September 2024
- Published by SAGE Publications in Advances in Wound Care
- Vol. 13 (9) , 426-434
Use of Serum Protein Measurements as Biomarkers that Can Predict the Outcome of Diabetic Foot Ulceration
Objectives: To identify proteins that are prognostic for diabetic foot ulcer (DFU) healing and may serve as biomarkers for its management serum samples were analyzed from diabetic (DM) patients. Approach: The serum specimens that were evaluated in this study were obtained from DM patients with DFU who participated in a prospective study and were seen bi-weekly until they healed their ulcer or the exit visit at 12 weeks. The group was divided into Healers (who healed their DFU during the study) and Non-Healers. Results: IL-10, IL-4, IL-5, IL-6, IL-13 and INFγ, were higher in the Healers while Fractalkine, IL-8, and TNFα were higher in the Non-Healers. The trajectory of IL-10 levels remained stable over time within and across groups, resulting in a strong prognostic ability for the prospective DFU healing course. Classification and Regression Tree (CART) analysis created an 11-node decision tree with healing status as the categorical response. Innovation: Consecutive measurements of proteins associated with wound healing can identify biomarkers that can predict DFU healing over a 12-week period. IL-10 was the strongest candidate for prediction. Conclusion: Measurement of serum proteins can serve as a successful biomarker in guiding clinical management of DFU. The data also indicate likely superior performance of building a multi-protein biomarker score instead of relying on single biomarkers.
- 1 September 2024
- Published by SAGE Publications in Advances in Wound Care
- Vol. 13 (9) , 426-434
Use of Serum Protein Measurements as Biomarkers that Can Predict the Outcome of Diabetic Foot Ulceration
Objectives: To identify proteins that are prognostic for diabetic foot ulcer (DFU) healing and may serve as biomarkers for its management serum samples were analyzed from diabetic (DM) patients. Approach: The serum specimens that were evaluated in this study were obtained from DM patients with DFU who participated in a prospective study and were seen bi-weekly until they healed their ulcer or the exit visit at 12 weeks. The group was divided into Healers (who healed their DFU during the study) and Non-Healers. Results: IL-10, IL-4, IL-5, IL-6, IL-13 and INFγ, were higher in the Healers while Fractalkine, IL-8, and TNFα were higher in the Non-Healers. The trajectory of IL-10 levels remained stable over time within and across groups, resulting in a strong prognostic ability for the prospective DFU healing course. Classification and Regression Tree (CART) analysis created an 11-node decision tree with healing status as the categorical response. Innovation: Consecutive measurements of proteins associated with wound healing can identify biomarkers that can predict DFU healing over a 12-week period. IL-10 was the strongest candidate for prediction. Conclusion: Measurement of serum proteins can serve as a successful biomarker in guiding clinical management of DFU. The data also indicate likely superior performance of building a multi-protein biomarker score instead of relying on single biomarkers.
- 1 September 2024
- Published by SAGE Publications in Advances in Wound Care
- Vol. 13 (9) , 435-445
Use of Therapeutic RNAs to Accelerate Wound Healing in Diabetic Rabbit Wounds
Objective: To evaluate the efficacy of layer-by-layer (LbL) formulated therapeutic RNAs that inhibit PHD2 and microRNA-210 (miR-210), to improve impaired diabetic wound healing. Approach: We employed the diabetic neuroischemic rabbit model of impaired wound healing. Diabetes was induced in the rabbits with alloxan, and neuroischemia was induced by ligating the central neurovascular bundle of each ear. Four 6-mm full-thickness wounds were creating on each ear. A layer-by-layer (LbL) technique was employed to conformally coat the wound dressings with a chemically modified antisense RNA (antimiR) against miR-210 and an sshRNA targeting PHD2. Results: Wound healing was improved by the antimiR-210 but not the PHD2-sshRNA. Specific knockdown of miR-210 in tissue as measured by RT-qPCR was approximately 8 Ct greater than nonspecific controls, and this apparent level of knockdown (>99%) suggests that delivery to the tissue is highly efficient at the administered dose. Innovation: Use of novel therapeutic RNAs and the LbL system to deliver them to the diabetic wound. Conclusion: Healing of ischemic/neuropathic wounds in diabetic rabbits was accelerated upon inhibition of miR-210 by LbL delivery to the wound bed of a chemically modified antisense RNA targeting this microRNA.
- 1 September 2024
- Published by SAGE Publications in Advances in Wound Care
- Vol. 13 (9) , 435-445
Use of Therapeutic RNAs to Accelerate Wound Healing in Diabetic Rabbit Wounds
Objective: To evaluate the efficacy of layer-by-layer (LbL) formulated therapeutic RNAs that inhibit PHD2 and microRNA-210 (miR-210), to improve impaired diabetic wound healing. Approach: We employed the diabetic neuroischemic rabbit model of impaired wound healing. Diabetes was induced in the rabbits with alloxan, and neuroischemia was induced by ligating the central neurovascular bundle of each ear. Four 6-mm full-thickness wounds were creating on each ear. A layer-by-layer (LbL) technique was employed to conformally coat the wound dressings with a chemically modified antisense RNA (antimiR) against miR-210 and an sshRNA targeting PHD2. Results: Wound healing was improved by the antimiR-210 but not the PHD2-sshRNA. Specific knockdown of miR-210 in tissue as measured by RT-qPCR was approximately 8 Ct greater than nonspecific controls, and this apparent level of knockdown (>99%) suggests that delivery to the tissue is highly efficient at the administered dose. Innovation: Use of novel therapeutic RNAs and the LbL system to deliver them to the diabetic wound. Conclusion: Healing of ischemic/neuropathic wounds in diabetic rabbits was accelerated upon inhibition of miR-210 by LbL delivery to the wound bed of a chemically modified antisense RNA targeting this microRNA.
- Open Access
- 9 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (32) , eado7538
Water-powered, electronics-free dressings that electrically stimulate wounds for rapid wound closure
Chronic wounds affect ~2% of the U.S. population and increase risks of amputation and mortality. Unfortunately, treatments for such wounds are often expensive, complex, and only moderately effective. Electrotherapy represents a cost-effective treatment; however, its reliance on bulky equipment limits its clinical use. Here, we introduce water-powered, electronics-free dressings (WPEDs) that offer a unique solution to this issue. The WPED performs even under harsh conditions—situations wherein many present treatments fail. It uses a flexible, biocompatible magnesium-silver/silver chloride battery and a pair of stimulation electrodes; upon the addition of water, the battery creates a radial electric field. Experiments in diabetic mice confirm the WPED’s ability to accelerate wound closure and promote healing by increasing epidermal thickness, modulating inflammation, and promoting angiogenesis. Across preclinical wound models, the WPED-treated group heals faster than the control with wound closure rates comparable to treatments requiring expensive biologics and/or complex electronics. The results demonstrate the WPED’s potential as an effective and more practical wound treatment dressing.
- 9 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (32) , eado7538
Open AccessWater-powered, electronics-free dressings that electrically stimulate wounds for rapid wound closure
Chronic wounds affect ~2% of the U.S. population and increase risks of amputation and mortality. Unfortunately, treatments for such wounds are often expensive, complex, and only moderately effective. Electrotherapy represents a cost-effective treatment; however, its reliance on bulky equipment limits its clinical use. Here, we introduce water-powered, electronics-free dressings (WPEDs) that offer a unique solution to this issue. The WPED performs even under harsh conditions—situations wherein many present treatments fail. It uses a flexible, biocompatible magnesium-silver/silver chloride battery and a pair of stimulation electrodes; upon the addition of water, the battery creates a radial electric field. Experiments in diabetic mice confirm the WPED’s ability to accelerate wound closure and promote healing by increasing epidermal thickness, modulating inflammation, and promoting angiogenesis. Across preclinical wound models, the WPED-treated group heals faster than the control with wound closure rates comparable to treatments requiring expensive biologics and/or complex electronics. The results demonstrate the WPED’s potential as an effective and more practical wound treatment dressing.
- 31 May 2024
- Published by Springer Nature
- p. 273-286
Role of Extracellular Vesicles, Modified mRNA, miRNA, and siRNA in Diabetic Lower Extremity Complications
- 31 May 2024
- Published by Springer Nature
- p. 273-286
Role of Extracellular Vesicles, Modified mRNA, miRNA, and siRNA in Diabetic Lower Extremity Complications
- Top Cited PapersOpen Access
- 22 May 2024
- Published by Springer Nature in Nature
- Vol. 630 (8016) , 360-367
Adhesive anti-fibrotic interfaces on diverse organs
Implanted biomaterials and devices face compromised functionality and efficacy in the long term owing to foreign body reactions and subsequent formation of fibrous capsules at the implant–tissue interfaces1–4. Here we demonstrate that an adhesive implant–tissue interface can mitigate fibrous capsule formation in diverse animal models, including rats, mice, humanized mice and pigs, by reducing the level of infiltration of inflammatory cells into the adhesive implant–tissue interface compared to the non-adhesive implant–tissue interface. Histological analysis shows that the adhesive implant–tissue interface does not form observable fibrous capsules on diverse organs, including the abdominal wall, colon, stomach, lung and heart, over 12 weeks in vivo. In vitro protein adsorption, multiplex Luminex assays, quantitative PCR, immunofluorescence analysis and RNA sequencing are additionally carried out to validate the hypothesis. We further demonstrate long-term bidirectional electrical communication enabled by implantable electrodes with an adhesive interface over 12 weeks in a rat model in vivo. These findings may offer a promising strategy for long-term anti-fibrotic implant–tissue interfaces.
- 22 May 2024
- Published by Springer Nature in Nature
- Vol. 630 (8016) , 360-367
Top Cited PapersOpen AccessAdhesive anti-fibrotic interfaces on diverse organs
Implanted biomaterials and devices face compromised functionality and efficacy in the long term owing to foreign body reactions and subsequent formation of fibrous capsules at the implant–tissue interfaces1–4. Here we demonstrate that an adhesive implant–tissue interface can mitigate fibrous capsule formation in diverse animal models, including rats, mice, humanized mice and pigs, by reducing the level of infiltration of inflammatory cells into the adhesive implant–tissue interface compared to the non-adhesive implant–tissue interface. Histological analysis shows that the adhesive implant–tissue interface does not form observable fibrous capsules on diverse organs, including the abdominal wall, colon, stomach, lung and heart, over 12 weeks in vivo. In vitro protein adsorption, multiplex Luminex assays, quantitative PCR, immunofluorescence analysis and RNA sequencing are additionally carried out to validate the hypothesis. We further demonstrate long-term bidirectional electrical communication enabled by implantable electrodes with an adhesive interface over 12 weeks in a rat model in vivo. These findings may offer a promising strategy for long-term anti-fibrotic implant–tissue interfaces.
- 6 March 2024
- Published by Wiley in Advanced Materials Technologies
- Vol. 9 (11)
Intelligent In situ Printing of Multimaterial Bioinks for First‐Aid Wound Care Guided by Eye‐In‐Hand Robot Technology
INSIGHT (INtelligent in situ printing Guided by Eye‐in‐Hand robot Technology), an innovative computer vision‐enabled system that combines a depth camera with a 6‐degree of freedom robot arm, empowering it to identify arbitrary areas at various angles through real time adjustments and to enable volumetric printing performed by dynamic image recognition based on color and contour differences is presented. Continuous targeting of multiple wounds at different locations is achieved. The optimized pneumatic valve synchronized with the INSIGHT can print multiple inks with diverse rheological properties to fabricate scaffolds and bandages with the capacity to treat various types of wounds. The design of dual printed modes, such as extrusion and spray, can significantly decrease printing time for large‐scale wounds on an ex vivo porcine model. INSIGHT demonstrates its ability to treat diabetic wounds, using a microgel‐based ink possessing an inherent porous microstructure to facilitate cell infiltration. In vivo verification highlights its adaptability to enable customized care for rapid emergency treatment of trauma patients.
- 6 March 2024
- Published by Wiley in Advanced Materials Technologies
- Vol. 9 (11)
Intelligent In situ Printing of Multimaterial Bioinks for First‐Aid Wound Care Guided by Eye‐In‐Hand Robot Technology
INSIGHT (INtelligent in situ printing Guided by Eye‐in‐Hand robot Technology), an innovative computer vision‐enabled system that combines a depth camera with a 6‐degree of freedom robot arm, empowering it to identify arbitrary areas at various angles through real time adjustments and to enable volumetric printing performed by dynamic image recognition based on color and contour differences is presented. Continuous targeting of multiple wounds at different locations is achieved. The optimized pneumatic valve synchronized with the INSIGHT can print multiple inks with diverse rheological properties to fabricate scaffolds and bandages with the capacity to treat various types of wounds. The design of dual printed modes, such as extrusion and spray, can significantly decrease printing time for large‐scale wounds on an ex vivo porcine model. INSIGHT demonstrates its ability to treat diabetic wounds, using a microgel‐based ink possessing an inherent porous microstructure to facilitate cell infiltration. In vivo verification highlights its adaptability to enable customized care for rapid emergency treatment of trauma patients.